1. Home
  2. PLUR

as of 11-03-2026 1:28pm EST

$1.26
+$0.06
+5.00%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Founded: 2001 Country:
Israel
Israel
Employees: N/A City: HAIFA
Market Cap: 12.5M IPO Year: 2026
Target Price: N/A AVG Volume (30 days): 57.2K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.44 EPS Growth: 31.46
52 Week Low/High: $0.85 - $4.87 Next Earning Date: 11-16-2026
Revenue: $1,016,000 Revenue Growth: -23.95%
Revenue Growth (this year): 902.46% Revenue Growth (next year): -100.00%
P/E Ratio: -0.49 Index: N/A
Free Cash Flow: -20221000.0 FCF Growth: N/A

Stock Insider Trading Activity of Pluri Inc. (PLUR)

Manieu Alexandre Weinstein

Director, 10% Owner

Buy
PLUR Oct 23, 2026

Avg Cost/Share

$1.50

Shares

833,334

Total Value

$1,250,001.00

Owned After

2,083,334

SEC Form 4

Share on Social Networks: